Cardio-oncology & otherDiagnostic or prognostic study
Cell-free DNA methylome analysis for early preeclampsia prediction
- Diagnostic accuracy study
- external validation cohort from two centres
Authors' conclusion
These preliminary results suggest that cell-free DNA methylation profiling is a promising tool for presymptomatic PE risk assessment, and has the potential to improve treatment and follow-up in the obstetric clinic.
Study context
- Population
- Pregnant women, first trimester (around 12 weeks of gestation), risk of early-onset preeclampsiaabout one-third early-onset preeclampsia (PE)
- Participants
- 498 women
- Comparison
- cfDNA methylation risk model, alone and combined with maternal risk factors
- Outcome
- Prediction of early-onset preeclampsia
- Follow-up
- Around 12 weeks of gestation (range 9-14 weeks)
Performance
As reported in the abstract
Early-onset PE prediction, external validation
| Test or model | AUC | Sensitivity at 80% specificity |
|---|---|---|
| Methylation model | 0.75 | |
| Combined risk score | 0.85 | 72% |
Further findings
Methylation differences between control and PE pregnancies
- Enabled risk stratification at PE diagnosis and presymptomatically
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Cell-free DNA methylome analysis for early preeclampsia prediction. Nat Med. Published 28 August 2023. doi:10.1038/s41591-023-02510-5
Summarised from the published abstract; every number is checked against it